Search results
-
AbbVie's telisotuzumab conjugate take two
… relapsed colorectal cancer, where first-in-human data at ASCO 2024 showed 2.4mg/kg or higher dose scoring a 38% ORR …
- 06/11/2025 - 14:48 -
AbbVie gets a cMet niche
… 2nd-line+ solid tumours, incl CRC (+/- Avastin) Data at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses …
- 05/19/2025 - 10:52 -
Qilu nabs a new B7-H3 contender
… In a Chinese phase 1/2 solid tumour trial reported at ASCO 2024, MHB088C produced a 61% overall response rate …
- 05/13/2025 - 16:22 -
Ivonescimab goes post-checkpoint
… chemo; data due mid-2025 Chemo combo, vs chemo; data at ASCO 2024 2nd-line NSCLC (post PD-(L)1) (none) …
- 04/17/2025 - 13:28 -
Another false dawn for p53
… presence KT-253* Kymera Ph1 data at ASCO 2024; Kymera no longer active in oncology …
- 04/16/2025 - 10:14 -
AACR 2025 preview – distressed biotechs seek redemption
… CT038 Ph1 +/- toripalimab Had monoRx data at ASCO 2024 29 April clinical trials minisymposium …
- 03/28/2025 - 08:55 -
AACR 2025 preview – Roche's TIGIT postmortem
… AffyImmune CT206 Ph1 thyroid cancers Had ASCO 2024 data Merck had more success with …
- 04/04/2025 - 13:32 -
ELCC 2025 – AstraZeneca gets a survival boost from Laura
… in stage III EGFRm NSCLC ELCC 2025 ASCO 2024 Data maturity 31% 20% … HR=0.81; CI 0.42-1.56 Source: ELCC 2025 & ASCO 2024. Conferences Trial …
- 03/26/2025 - 08:17 -
Aadi gets an ADC makeover
… Only ADC in clinic is AbbVie’s ABBV-706 ( early data at ASCO 2024 ) Source: OncologyPipeline & company …
- 03/20/2025 - 15:37 -
Make or break time for Caribou
… disappointed with its allogeneic Car-T project CB-010 at ASCO 2024 , will soon have a chance to redeem itself. In … 14.8mth Note: *2L LBCLC subgroup. Source: ASCO 2024 & product labels. Caribou has therefore …
- 03/25/2025 - 15:35
